Biocare Medical

About Biocare Medical

Established in 1997 by co-founders Roy Paxton Yih and Gene Castagnini, Biocare Medical, LLC operates as a key manufacturer of instrumentation and reagents for immunohistochemistry (IHC) and molecular pathology. The firm is strategically focused on the cancer and infectious disease diagnostic and research markets, providing tools that enhance diagnostic confidence and efficiency. Revenue is generated through the direct sale of its products on a B2B basis to a diverse client portfolio that includes clinical histology laboratories, pharmaceutical and biotechnology companies, contract research organizations (CROs), and various academic, government, and military labs. The business model involves fixed-price sales of equipment and consumables, with transactions handled through direct agreements and a global distribution network spanning North America, Europe, and Asia.

Biocare Medical develops and supplies a comprehensive range of products, including primary antibodies, detection systems, and automated slide-staining instruments. A notable offering is its multiplex IHC technology, which permits the visualization of multiple markers on a single tissue sample, thereby conserving precious tissue, reducing reagent consumption, and improving turnaround times. The company's instrumentation portfolio includes the VALENT® and intelliPATH® automated staining platforms. The VALENT® system, introduced in 2019, is a fully automated, open platform with a 48-slide capacity, enabling laboratories to use reagents from various sources. The intelliPATH FLX is another open, continuous random access IHC instrument. For specialized research needs, the PromARK™ micro-polymer detection systems are designed specifically for use on animal tissues, offering high sensitivity while minimizing cross-reactivity.

The company has achieved significant milestones, including being named to the Inc. 5000 list of fastest-growing private companies in 2009 after recording a 93.1% sales growth from 2005-2008. In December 2021, Global Healthcare Opportunities (GHO Capital) acquired the company from Excellere Partners, with Excellere remaining a significant partner. This investment aims to accelerate research and development, support new product launches, and facilitate international expansion. A key strategic move was the acquisition of Empire Genomics in November 2022, a market leader in molecular biomarkers. This acquisition significantly expanded Biocare's molecular portfolio to over one million biomarkers, integrating Empire Genomics' expertise in designing and manufacturing molecular probes for cancer research and diagnostics.